

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT RESIGNATION OF NON-EXECUTIVE DIRECTOR AND CHANGE OF JOINT COMPANY SECRETARY

The board of directors (the “**Board**”) of Sinopharm Group Co. Ltd.(the “**Company**”) announces that on 28 December 2018, due to work adjustment, Mr. Wu Yijian (“**Mr. Wu**”) tendered his resignation as a non-executive director of the Company, a member of the audit committee of the Board (the “**Audit Committee**”), a member of the remuneration committee of the Board (the “**Remuneration Committee**”)and a member of the strategy and investment committee of the Board (the “**Strategy and Investment Committee**”) with immediate effect. Mr. Wu has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation as non-executive director that needs to be brought to the attention of the shareholders and creditors of the Company.

On the same day, due to work rearrangement, Mr. Cai Maisong (“**Mr. Cai**”) has tendered his resignation from his positions as secretary to the Board, joint company secretary and authorised representative of the Company with immediate effect. Mr. Cai will remain as a vice president of the Company after his resignation of the positions above. Mr. Wu was appointed by the Board on 28 December 2018 as the new secretary to the Board, joint company secretary and authorised representative of the Company with immediate effect.

The Board also announces that, the Company has applied for, and The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) has granted a waiver to the Company from strict compliance with the requirements under Rule 3.28 and Rule 8.17 of the Listing Rules for a period of three years commencing from the date of appointment of Mr. Wu as the joint company secretary of the Company, on the condition that Mr. Wu will be assisted by Dr. Liu Wei (“**Dr. Liu**”) to acquire the relevant experience within the meaning of Rule 3.28 of the Listing Rules and to discharge his duties as

the joint company secretary of the Company. Dr. Liu is a solicitor qualified to practice law in Hong Kong and England. Dr. Liu has been serving as the joint company secretary of the Company since 24 August 2011.

Biographical details of Mr. Wu Yijian are set out below:

Mr. Wu Yijian, aged 48, served as a non-executive director of the Company from June 2016 to September 2017 and from March 2018 to December 2018. Mr. Wu graduated from Shanghai Medical University with a bachelor's degree in medicine in July 1993. Mr. Wu obtained his master's degree in business administration from Tsinghua University in July 2003, his joint master's degree in professional accounting for senior accountant from the Chinese University of Hong Kong and Shanghai National Accounting Institute in November 2014, and completed the courses for the general manager in the China Europe International Business School of Management in July 2007. Mr. Wu has served in Sanjiu Enterprise from July 1993 to May 2004 and successively served as sales director of Shenzhen Sanjiu Pharmaceutical Trading Co., Ltd., the chief operating officer of Sanjiu Pharmaceutical Chain Co., Ltd. and the deputy general manager of Shanghai Sanjiu Pharmaceutical Technology Development Co., Ltd. Mr. Wu served in Shanghai Fosun Pharmaceutical (Group) Co., Ltd. from June 2004 to December 2014 and successively served as the general manager of Shanghai Fosun Pharmaceutical Investment Co., Ltd., general manager of Shanghai Fosun Pharmaceutical Co., Ltd., general manager of Shanghai Fumei Pharmacy Co., Ltd. and other positions. Mr. Wu served as the vice president of Shanghai Yuyuan Tourist Mart Co., Ltd. from January 2014 to December 2015. Mr. Wu served as the president assistant and the director of the commercial pharmaceutical management committee of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. from January 2016 to December 2018. Currently, Mr. Wu also serves as a director of Sinopharm Industrial Investment Co., Ltd. and the chairman of the supervisory committee of China National Accord Medicines Corporation Ltd.

The Board would like to take this opportunity to express its gratitude to Mr. Cai for his contribution to the Company during his tenure as the secretary to the Board, joint company secretary and authorised representative of the Company.

By order of the Board
Sinopharm Group Co. Ltd.
Li Zhiming
Chairman

Shanghai, the PRC
28 December 2018

As at the date of this announcement, the executive directors of the Company are Mr. Li Zhiming, Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Wang Qunbin, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong and Mr. Wen Deyong; and the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Tan Wee Seng, Mr. Liu Zhengdong, Mr. Zhuo Fumin and Mr. Chen Fangruo.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*